Abstract Number: L15 • ACR Convergence 2023
AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Background/Purpose: AR882 is a novel and selective URAT1 inhibitor currently in clinical stage development for the treatment of gout and tophaceous gout and has demonstrated…Abstract Number: 0238 • ACR Convergence 2023
Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature
Background/Purpose: Uniform terminology with standardised definitions for the various elements and states of a disease ensure accurate and consistent technical communication. In 2019 the Gout…Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…Abstract Number: 1110 • ACR Convergence 2023
Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout
Background/Purpose: In early phase studies AR882 exhibited good dose proportionality, long half-life and dose-dependent serum urate (sUA) lowering effect in a broad range of doses…Abstract Number: 2428 • ACR Convergence 2023
Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors
Background/Purpose: A recent UK study reported a transient increased cardiovascular risk after gout flare episodes [Cipolletta et al. JAMA 2022], which may translate to premature…Abstract Number: 0239 • ACR Convergence 2023
Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database
Background/Purpose: Gout is a common inflammatory arthropathy characterized by pain, joint swelling, and monosodium urate crystal deposits in joints, organs, and soft tissues.1 While gout…Abstract Number: 0812 • ACR Convergence 2023
Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process
Background/Purpose: We described bands of fibers having deposited orderly arrayed monosodium urate (MSU) crystals suggesting the need for protein templates to start crystallization [PMID 9709185].…Abstract Number: 1113 • ACR Convergence 2023
Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients
Background/Purpose: The management of gout remains poor despite the availability of effective medications and recommendation of a treat-to-target treatment strategy using of urate-lowering therapy (ULT).…Abstract Number: 2505 • ACR Convergence 2023
Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders
Background/Purpose: Interleukin-1 receptor-associated kinase 4 (IRAK4), is a key node that mediates inflammatory signaling in response to activation of toll-like receptor (TLR) and IL-1 receptor…Abstract Number: 0240 • ACR Convergence 2023
Gout: A Gateway to Chronic Opioid Use?
Background/Purpose: Painful gout flares often lead to healthcare visits which, based on prior reports, results in the use of opioid therapy for flare management, despite…Abstract Number: 0813 • ACR Convergence 2023
Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants
Background/Purpose: The prevalence of sonographic monosodium urate (MSU) crystal deposition and inflammation in patients with gout in remission is unknown. In 2022, we reported a…Abstract Number: 1114 • ACR Convergence 2023
Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout
Background/Purpose: To find out if a Dual energy CT can detect monosodium urate deposition in carotid arteries and whether the presence of monosodium urate crystals…Abstract Number: 2563 • ACR Convergence 2023
Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study
Background/Purpose: Gut microbiota has been increasingly recognized as important and novel targets for rheumatic diseases. However, previous studies mostly examined the associations, leaving causality largely…Abstract Number: 0241 • ACR Convergence 2023
Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial
Background/Purpose: Initiating urate-lowering therapy (ULT) in gout is known to precipitate flares, which can lead to decreased adherence and suboptimal outcomes. Until recently, there has…Abstract Number: 0814 • ACR Convergence 2023
Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial
Background/Purpose: To optimally manage gout, the ACR recommends a treat-to-target (T2T) strategy, which entailsthe titration of urate-lowering therapy (ULT) to achieve and maintain a serum…
- 1
- 2
- 3
- …
- 40
- Next Page »